Repare Therapeutics Inc.
RPTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $53 | $51 | $132 | $8 |
| % Growth | 4.6% | -61.2% | 1,634.6% | – |
| Cost of Goods Sold | $13 | $13 | $117 | $88 |
| Gross Profit | $40 | $38 | $15 | -$80 |
| % Margin | 75% | 74.1% | 11.5% | -1,056% |
| R&D Expenses | $117 | $134 | $121 | $91 |
| G&A Expenses | $30 | $34 | $33 | $26 |
| SG&A Expenses | $32 | $34 | $35 | $28 |
| Sales & Mktg Exp. | $3 | $0 | $2 | $2 |
| Other Operating Expenses | -$15 | -$13 | -$121 | -$91 |
| Operating Expenses | $134 | $154 | $35 | $28 |
| Operating Income | -$94 | -$116 | -$20 | -$109 |
| % Margin | -174.9% | -227.3% | -15% | -1,429.7% |
| Other Income/Exp. Net | $10 | $13 | $6 | $0 |
| Pre-Tax Income | -$83 | -$103 | -$14 | -$109 |
| Tax Expense | $1 | -$9 | $15 | -$2 |
| Net Income | -$85 | -$94 | -$29 | -$107 |
| % Margin | -158.4% | -183.4% | -22% | -1,406.7% |
| EPS | -2 | -2.23 | -0.69 | -2.83 |
| % Growth | 10.3% | -223.2% | 75.6% | – |
| EPS Diluted | -2 | -2.23 | -0.69 | -2.83 |
| Weighted Avg Shares Out | 42 | 42 | 42 | 38 |
| Weighted Avg Shares Out Dil | 42 | 42 | 42 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $13 | $6 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $1 |
| EBITDA | -$90 | -$114 | -$18 | -$107 |
| % Margin | -168.7% | -223.5% | -13.5% | -1,410.4% |